An interesting synthetic-lethality therapy principle involving the SWI/SNF catalytic subunit, BRG1/SMARCA4, frequently deficient in non-small-cell lung carcinomas by BRM-ATPase inhibitors targeting another SWI/SNF subunit, has been proposed in a recent study [163]. The gene discussed is SMARCA4; the disease is non-small cell lung carcinoma.